|Drug Name:||Labetalol HCl|
|Other Info:||There have been reversible increases of serum transaminases in 4% of patients treated with labetalol and tested, and more rarely, reversible increases in blood urea.|
Labetalol HCl Tablets are indicated in the management of hypertension.Labetalol HCl Tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.
Labetalol HCl Tablets are contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see WARNINGS).Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.
Severe hepatocellular injury, confirmed by rechallenge in at least one case, occurs rarely with therapy with labetalol.
The hepatic injury is usually reversible, but hepatic necrosis and death have been reported.
Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology.
Similar hepatic events have been reported with a related compound, dilevalol HCl, including two deaths.
Dilevalol HCl is one of the four isomers of labetalol HCl.
Thus, for patients taking labetalol, periodic determination of suitable hepatic laboratory tests would be appropriate.
Laboratory testing should also be done at the very first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness, or unexplained “flu-like” symptoms).If the patient has jaundice or laboratory evidence of liver injury, labetalol should be stopped and not restarted.